Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.50 |
| ▸ | RXRA | P19793 | 1/20 | 0.47 |
| ▸ | RXRB | P28702 | 1/20 | 0.47 |
| ▸ | RXRG | P48443 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | PPARD | Q03181 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6451526 | 0.82 | MAPK1 (0.41) | PTGDR2RXRARXRBRXRGMAPT | |
| SCHEMBL7825959 | 0.79 | NPC1 (0.50) | MAPTKDM4EALDH1A1PKMNPC1 | |
| SCHEMBL7061525 | 0.78 | PTGDR2 (0.44) | PTGDR2RXRARXRBRXRGPKM | |
| SCHEMBL28271027 | 0.78 | NPC1 (0.49) | MAPTKDM4EALDH1A1PKMNPC1 | |
| SCHEMBL6450429 | 0.77 | PTGDR2 (0.51) | PTGDR2RXRARXRBRXRGMAPT | |
| SCHEMBL8189292 | 0.76 | NPC1 (0.48) | MAPTKDM4EALDH1A1PKMNPC1 | |
| SCHEMBL7241440 | 0.76 | NPC1 (0.48) | MAPTKDM4EALDH1A1PKMNPC1 | |
| SCHEMBL7062579 | 0.76 | PPARG (0.45) | PTGDR2KDM4EALDH1A1PPARD | |
| SCHEMBL23232179 | 0.74 | ALDH1A1 (0.46) | KDM4EALDH1A1NPC1RAB9AHTT | |
| SCHEMBL19318218 | 0.74 | ALDH1A1 (0.59) | ALDH1A1NPC1RAB9APDE4BHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030139453-A1 | Difluorobutyric acid metalloprotease inhibitors | THE PROCTER & GAMBLE COMPANY | 2003-07-24 | — | — | US | claimed |
| EP-1265865-A2 | DIFLUOROBUTYRIC ACID DERIVATIVES AND THEIR USE AS METALLOPROTEASE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2002-12-18 | — | — | EP | claimed |
| WO-2001070693-A2 | DIFLUOROBUTYRIC ACID DERIVATIVES AND THEIR USE AS METALLOPROTEASE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2001-09-27 | — | — | WO | claimed |
| US-6852751-B2 | Difluorobutyric acid metalloprotease inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2005-02-08 | — | — | US | disclosed |
| US-20030139453-A1 | Difluorobutyric acid metalloprotease inhibitors | THE PROCTER & GAMBLE COMPANY | 2003-07-24 | — | — | US | disclosed |
| EP-1265865-A2 | DIFLUOROBUTYRIC ACID DERIVATIVES AND THEIR USE AS METALLOPROTEASE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2002-12-18 | — | — | EP | disclosed |
| WO-2001070693-A2 | DIFLUOROBUTYRIC ACID DERIVATIVES AND THEIR USE AS METALLOPROTEASE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2001-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139453-A1 | Difluorobutyric acid metalloprotease inhibitors | DPEP1, TMPRSS15, FAP | PTGDR2 769/4885RXRA 3683/4885RXRB 2745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.